Sumitomo Chemical India Ltd
Sumitomo Chemical India Ltd. (SCIL) is one of the leading players in the industry which has a balanced portfolio of technical as well as formulation products along with backward integration for some products. The Company is known for domestic marketing of proprietary products of its Japanese parent -Sumitomo Chemical Company Limited in agrochemicals, animal nutrition, and environmental health business segments. With the integration of Excel Crop Care Limited, the Company now has a strong portfolio of generics in addition to specialty products and a strong combined marketing network. With this integration, the Company has moved up several notches in the pecking order of the Indian crop protection industry. SCIL has also marked its presence in Africa and several other geographies of the world.[1] [2]
- Market Cap ₹ 26,100 Cr.
- Current Price ₹ 523
- High / Low ₹ 628 / 446
- Stock P/E 52.0
- Book Value ₹ 58.0
- Dividend Yield 0.17 %
- ROCE 25.1 %
- ROE 18.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 37.5%
Cons
- Stock is trading at 8.93 times its book value
- The company has delivered a poor sales growth of 4.98% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals
Part of BSE 500 Nifty 500 BSE SmallCap BSE Allcap BSE Commodities
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 635 | 671 | 724 | 799 | 1,911 | 2,223 | 2,423 | 2,643 | 3,060 | 3,511 | 2,833 | 3,090 | |
| 587 | 614 | 635 | 698 | 1,691 | 1,932 | 2,088 | 2,155 | 2,458 | 2,843 | 2,358 | 2,468 | |
| Operating Profit | 48 | 57 | 89 | 101 | 219 | 291 | 335 | 488 | 603 | 668 | 474 | 623 |
| OPM % | 8% | 8% | 12% | 13% | 11% | 13% | 14% | 18% | 20% | 19% | 17% | 20% |
| 3 | 8 | 26 | 10 | 31 | -0 | -20 | 19 | 36 | 45 | 96 | 119 | |
| Interest | 2 | 1 | 1 | 1 | 5 | 5 | 7 | 7 | 8 | 6 | 5 | 5 |
| Depreciation | 6 | 6 | 7 | 7 | 24 | 28 | 41 | 47 | 45 | 52 | 61 | 63 |
| Profit before tax | 43 | 58 | 107 | 103 | 221 | 258 | 267 | 453 | 586 | 655 | 503 | 674 |
| Tax % | 23% | 40% | 40% | 40% | 34% | 35% | 23% | 24% | 26% | 23% | 27% | 26% |
| 33 | 35 | 65 | 62 | 145 | 167 | 206 | 345 | 434 | 503 | 370 | 502 | |
| EPS in Rs | 4.12 | 6.92 | 8.69 | 10.09 | 7.41 | 10.06 | ||||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 38% | 18% | 12% | 12% | 12% | 80% | 21% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 5% |
| 3 Years: | 0% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 17% |
| 3 Years: | 5% |
| TTM: | 36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 7% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 21% |
| 3 Years: | 19% |
| Last Year: | 19% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 233 | 233 | 233 | 275 | 275 | 275 | 499 | 499 | 499 | 499 | 499 | 499 |
| Reserves | -36 | -2 | 63 | 360 | 665 | 761 | 710 | 1,029 | 1,425 | 1,881 | 1,941 | 2,397 |
| 0 | 0 | 0 | 0 | 10 | 20 | 36 | 33 | 38 | 34 | 25 | 45 | |
| 243 | 234 | 280 | 288 | 695 | 791 | 848 | 1,097 | 1,047 | 955 | 822 | 988 | |
| Total Liabilities | 440 | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 |
| 47 | 51 | 52 | 53 | 267 | 279 | 319 | 309 | 390 | 430 | 489 | 501 | |
| CWIP | 0 | 0 | 1 | 7 | 9 | 8 | 10 | 14 | 35 | 71 | 23 | 9 |
| Investments | 0 | 0 | 0 | 277 | 2 | 1 | 87 | 291 | 357 | 239 | 425 | 601 |
| 393 | 415 | 523 | 585 | 1,367 | 1,558 | 1,676 | 2,043 | 2,227 | 2,628 | 2,351 | 2,819 | |
| Total Assets | 440 | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 | 4 | 52 | -21 | 49 | 75 | 222 | 424 | 223 | 389 | 756 | 459 | |
| -8 | -8 | -5 | -289 | -40 | -35 | -118 | -282 | -281 | -327 | -426 | -404 | |
| -1 | 0 | -0 | 276 | 7 | -65 | -61 | -47 | -63 | -73 | -331 | -66 | |
| Net Cash Flow | 11 | -4 | 47 | -34 | 16 | -26 | 43 | 95 | -120 | -10 | -1 | -11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 83 | 92 | 101 | 105 | 110 | 128 | 117 | 101 | 98 | 91 | 90 |
| Inventory Days | 125 | 135 | 169 | 191 | 202 | 193 | 133 | 185 | 198 | 157 | 135 | 138 |
| Days Payable | 134 | 109 | 132 | 115 | 176 | 136 | 112 | 145 | 110 | 87 | 96 | 97 |
| Cash Conversion Cycle | 81 | 109 | 130 | 177 | 131 | 167 | 150 | 157 | 189 | 168 | 131 | 132 |
| Working Capital Days | 58 | 69 | 79 | 113 | 115 | 119 | 111 | 97 | 128 | 138 | 175 | 239 |
| ROCE % | 25% | 27% | 41% | 22% | 29% | 27% | 26% | 33% | 34% | 30% | 21% | 25% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
17 Jun - Of Schedule of Institutional Investors/Analyst meetings under the SEBI (LODR), Regulations 2015
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
3 Jun - Sumitomo Chemical India reports record FY25 profits, launches new patented products, and announces Rs. 65 Cr CAPEX expansions.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
28 May - Earnings call audio for Q4 and FY ended March 31, 2025, uploaded on company website.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
27 May - Investor Presentation for the quarter and year ended 31.03.2025
-
Appointment Of Secretarial Auditor
26 May - Appointment of M/s. M K Saraf & Associates LLP as secretarial auditors for five years.
Annual reports
Concalls
-
Jun 2025Transcript PPT
-
Jan 2025TranscriptNotesPPT
-
Nov 2024Transcript PPT
-
Jul 2024TranscriptNotesPPT
-
Jun 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT REC
-
Feb 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
Products
The company operates in agorchemicals, including insecticides, weedicides, fungicides, fumigants, rodenticides, plant growth nutrition products, bio-rationals, and plant growth regulators. It markets proprietary products from its Japanese parent, Sumitomo Chemical Co., in agrochemicals, animal nutrition, and environmental health.[1]
The products comprise conventional chemistry sourced from SCC, and biological products sourced from a USA-based subsidiary, Valent Biosciences LLC. [2]